Free tool
FAERS Monitor: Robaxin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011790 or its brand name (Robaxin, Methocarbamol). Reports on generic versions are filed under their own applications.
Reports
23,216
Serious
14,376
62% of reports
Hospitalization
6,997
Death reported
1,762
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain1,771
- nausea1,717
- fatigue1,706
- drug ineffective1,553
- headache1,339
- diarrhoea1,232
- fall1,119
- dyspnoea1,086
- arthralgia1,068
- off label use1,034
- dizziness985
- back pain949
- anxiety928
- vomiting887
- depression834
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 181 |
| 2005 | 231 |
| 2006 | 235 |
| 2007 | 164 |
| 2008 | 198 |
| 2009 | 297 |
| 2010 | 384 |
| 2011 | 433 |
| 2012 | 585 |
| 2013 | 579 |
| 2014 | 645 |
| 2015 | 1,189 |
| 2016 | 1,584 |
| 2017 | 1,296 |
| 2018 | 1,504 |
| 2019 | 1,679 |
| 2020 | 1,774 |
| 2021 | 1,427 |
| 2022 | 1,493 |
| 2023 | 1,504 |
| 2024 | 1,716 |
| 2025 | 2,253 |
| 2026 | 1,865 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,943 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| back painSignal | 949 | 3.7 | 3.5 | 1,891 |
| depressionSignal | 834 | 3.3 | 3.1 | 1,367 |
| fallSignal | 1,119 | 3.1 | 2.9 | 1,562 |
| anxietySignal | 928 | 3.0 | 2.8 | 1,215 |
| painSignal | 1,771 | 2.6 | 2.5 | 1,815 |
| arthralgiaSignal | 1,068 | 2.3 | 2.2 | 824 |
| fatigue | 1,706 | 2.0 | 1.9 | 866 |
| nausea | 1,717 | 2.0 | 1.9 | 846 |
| headache | 1,339 | 1.9 | 1.8 | 623 |
| dizziness | 985 | 1.8 | 1.7 | 351 |
| dyspnoea | 1,086 | 1.7 | 1.6 | 349 |
| diarrhoea | 1,232 | 1.7 | 1.6 | 390 |
| vomiting | 887 | 1.7 | 1.6 | 267 |
| off label use | 1,034 | 1.1 | 1.0 | 5 |
| drug ineffective | 1,553 | 1.1 | 1.0 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.